MYND Life Sciences (XCNQ:MYND) Equity-to-Asset : -8.32 (As of Jul. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MYND Life Sciences's Total Stockholders Equity for the quarter that ended in Jul. 2024 was C$-5.99 Mil. MYND Life Sciences's Total Assets for the quarter that ended in Jul. 2024 was C$0.72 Mil.

The historical rank and industry rank for MYND Life Sciences's Equity-to-Asset or its related term are showing as below:

XCNQ:MYND' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.99 Med: -5.82 Max: 0.63
Current: -8.32

During the past 3 years, the highest Equity to Asset Ratio of MYND Life Sciences was 0.63. The lowest was -15.99. And the median was -5.82.

XCNQ:MYND's Equity-to-Asset is ranked worse than
97.21% of 1505 companies
in the Biotechnology industry
Industry Median: 0.67 vs XCNQ:MYND: -8.32

MYND Life Sciences Equity-to-Asset Historical Data

The historical data trend for MYND Life Sciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Equity-to-Asset Chart

MYND Life Sciences Annual Data

Trend

Oct21

Oct22

Oct23

Equity-to-Asset

-0.03

-5.40

-6.24

MYND Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Equity-to-Asset	Get a 7-Day Free Trial										-15.99	-6.24	-6.94	-7.92	-8.32

Competitive Comparison of MYND Life Sciences's Equity-to-Asset

For the Biotechnology subindustry, MYND Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MYND Life Sciences's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MYND Life Sciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where MYND Life Sciences's Equity-to-Asset falls into.

Save Embed

;

Save Embed

;

MYND Life Sciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

MYND Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Equity to Asset (A: Oct. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-4.977	/	0.798
	=

MYND Life Sciences's Equity to Asset Ratio for the quarter that ended in Jul. 2024 is calculated as

Equity to Asset (Q: Jul. 2024 )	=	Total Stockholders Equity	/	Total Assets
	=	-5.989	/	0.72
	=

MYND Life Sciences (XCNQ:MYND) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

MYND Life Sciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

MYNDF:USA

Address

105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2

Website

https://www.myndsciences.com

MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.